Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $180.59 USD
Change Today +4.55 / 2.58%
Volume 1.5M
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ALEXION PHARMACEUTICALS INC (ALXN) in the last 6 months

Announced 12/19/14
502.00M for Moderna Therapeutics, Inc.
Private Placement

Moderna LLC announced that it will receive $502,168,634 in funding on December 19, 2014. The company will issue series E preferred units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. As of January 5, 2015, the company received $446,069,409 from 43 investors including new investors Viking Global Investors LP, Invus, RA Capital Management, and Wellington Management Company, LLP. The transaction included participation ...
Read More


ALXN's price was unchanged after the transaction was announced on 12/19/14.
Investor / Buyer
Alexion Pharmaceuticals, Inc.
AstraZeneca PLC
RA Capital Management, LLC
The Invus Group, LLC
Viking Global Investors L.P.
Wellington Management Company LLP
 
Announced 12/15/14
500.00M for Alexion Pharmaceuticals, Inc.
Buyback

Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN) announces a share repurchase program. Under the program, the company will repurchase up to $500 million of its common stock. The repurchases will be made from time to time on the open market, including through 10b5-1 trading plans, or through privately negotiated transactions, block transactions, or other techniques. The company expects to fund all purchases from cash on hand and future cash flows from operations. Repurchases ...
Read More


ALXN's price was unchanged after the transaction was announced on 12/15/14.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $180.59 USD +4.55

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,415 INR -30.30
Regeneron Pharmaceuticals Inc $454.50 USD +6.13
Sigma-Aldrich Corp $138.21 USD -0.02
Symrise AG €57.90 EUR -0.349
United Therapeutics Corp $172.96 USD +5.44
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 55.4x
Price/Sales 16.1x
Price/Book 10.9x
Price/Cash Flow 55.6x
TEV/Sales 15.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.